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Summary
Objective: To evaluate bodyweight gain during pregabalin therapy for epilepsy and
the utility of a short counseling program to prevent this side effect.
Methods: Randomized controlled trial on the effects of extended versus standard
patient counseling on the risk of bodyweight gain with 3- and 6-month follow-up
including a consecutive sample of adult outpatients with epilepsy eligible for prega-
balin add-on treatment (N = 98).
Results: The seizure response rate was about 30%, the seizure freedom rate was 5% at
the 6-month follow-up (intent-to-treat sample, N = 98). The median bodyweight gain
for the according-to-protocol sample (N = 62) was 4.0 kg with no effect of extended
counseling. Bodyweight gain was correlated with number of anticonvulsant drugs
(r = .32, p < .05).
Conclusions: Pregabalin treatment is associated with a high risk for bodyweight gain
which in part depends on total anticonvulsant drug load. This side effect cannot be
prevented by extended patient counseling within a standard clinical setting.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Bodyweight gain is a frequent adverse effect during
anticonvulsant (e.g., valproate, carbamazepine
and vigabatrine) and other neuropharmacological
therapies (e.g., atypical antipsychotics).1,2 Other
anticonvulsants may induce weight loss (e.g., zoni-
samide and topiramate) or may be weight-neutral* Corresponding author. Tel.: +49 228 287 16172;
fax: +49 228 287 14328.
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doi:10.1016/j.seizure.2007.10.004(e.g., levetiracetam).3 Weight gain is a serious side
effect because it may lead to non-compliance or
premature termination of the treatment. Further-
more, it has been implicated to have a negative
impact on glucose control, blood pressure, and lipid
profile and thus, it may increase the risk for diabetes
mellitus, heart disease or stroke.2
Pregabalin is a newly approved add-on
treatment for partial epilepsy in adult patients.4
The pharmacologically active S-enantiomer of. Published by Elsevier Ltd. All rights reserved.
328 C. Hoppe et al.3-aminomethyl-5-methyl-hexanoic acid binds with
high affinity and specificity to the alpha(2)-delta
subunit protein of voltage-gated calcium channels in
CNS tissues and acts as a presynaptic modulator of
excitatory neurotransmitter release by inhibiting
calcium influx.5 Although it is a structural analogue
of GABA, it does not act on GABA receptors or GABA
uptake.6 Four multi-centre, prospective rando-
mized double-blind placebo-controlled trials con-
firmed anticonvulsant efficacy against partial-onset
seizures in a total of 1396 patients.7 The responder
rate (i.e., percentage of patients with 50% or more
reduction in seizure frequency vs. baseline) in these
studies ranged from 14% to 51% of the enrolled
patients. In addition to somnolence, dizziness,
and ataxia, an increase in bodyweight of 7% or more
of the baseline body weight was reported as an
adverse effect in about 14% of the patients at a
dose of 600 mg/day.4
In Germany, pregabalin was available for add-on
treatment of epilepsy in adult patients since Sep-
tember 2004. We wanted to assess the therapeutic
and side effects right from the start of marketing.
Furthermore, being aware of the bodyweight gain
issue and its negative implications, we embedded a
randomized controlled trial to test the hypothesis
that more extended counseling of the patients may
help to prevent this adverse effect. This counseling
addressed the need for a weekly bodyweight control
as well as appropriate behavioral counter-measures
in case of bodyweight gain such as diet control (less
energy up-take) and physical exercise (more energy
expenditure).Methods
Randomized controlled trial
We defined two groups of patients. In one group
patients received extended counseling on the risk of
bodyweight gain during pregabalin add-on therapy
before titration. Extended counseling comprised a
comprehensive description of this risk factor and a
discussion of possible behavioral interventions that
may allow the patient to prevent weight gain. In
particular, the patients were asked to check their
bodyweight once a week and to react in case of
substantial bodyweight gain by reducing ingestion
and by increasing energy consumption (e.g., physi-
cal exercise). Patients received a written handout
with the essentials of these explanations (see
Appendix A). The study design did not allow con-
trolling patient compliance. In the other experimen-
tal group patients were generally informed about all
possible risks of pregabalin treatment includingbodyweight gain according to the clinical standards.
However, no particular emphasis was placed on
bodyweight gain and no suggestions to check body-
weight or to react in case of bodyweight gain were
given by the physician. The patients in the second
group did not receive the handout. Patients were
randomly allocated to either group. The follow-up
examinations were scheduled for 3 and 6 months.
Baseline medication and pregabalin
titration
It was intended that baseline medication generally
remains unchanged during the study if possible, but
clinically reasonable adaptations were permitted
within the protocol. Pregabalin was slowly titrated
with a daily dosage increment of 75 mg/week (0-0-
1, 1-0-1, 1-0-2, 2-0-2 and so on) thus reaching the
prescribed dosage of 300 or 450 mg/day after 4 or 6
weeks, respectively. Depending on seizure outcome
and adverse side effects at the 3-month follow-up
the dosage was further up or down-titrated accord-
ing to the same regimen.
Patients
From September 2004 to May 2005, adult out-
patients who appeared to be appropriate candidates
for pregabalin add-on treatment were asked to
participate in the study. From 140 adult patients
receiving pregabalin during this period, 98 patients
(70%) gave written informed consent and were
enrolled in the study. The general and clinical data
of these patients are given in Table 1.
Methods and measures
Bodyweight and body height were determined at
baseline in all patients. The body mass index (BMI)
was calculated (BMI (kg/cm2) = body weight (kg)/
body height (m)2). Bodyweight classes were assigned
according to the WHO International Classification of
Diseases (ICD-10): lowweight (18.5  BMI < 20), reg-
ular weight (20  BMI < 25), overweight (25  BMI
< 30), obesity grade I (30  BMI < 40). Bodyweight
was monitored at each follow-up.
All patients were asked to fill-out the Adverse
Event Profile questionnaire.8 This questionnaire
comprises 19 frequent adverse events including
bodyweight gain (item #14). Seizure frequency
per month was calculated from the patients’ seizure
diaries based on the last 3 months at baseline (retro-
spectively), 3- and 6-month follow-up. Simple par-
tial seizures (SPS), complex partial seizures (CPS),
generalized tonic-clonic seizures (GTCS) and drop
attacks were counted separately.
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Table 1 Study patient sample: general and clinical
data
Sample size 98
Male/female 55/43
Age (years) at baseline (S.D.) 38.4 (11.4)
Body weight (kg) (S.D.) 73 (15)
Body length (m) (S.D.) 1.71 (0.11)
Body mass index (S.D.) 24.9 (3.9)
Body weight classesa
Low (BMI < 20) 9 (9%)
Regular (20  BMI < 25) 46 (46%)
Overweight (25  BMI < 30) 32 (33%)
Adipositas I (30  BMI < 40) 11 (11%)
Epilepsy etiology:
symptomatic/kryptogenic
77/21
Seizure types: SPS/CPS/GTCS/Drop 13/81/85/3
Seizure frequency per
month–—median (S.D.)
7 (17.5)
Number of AED (baseline): 1/2/3/4 8/37/38/15
Previous epilepsy surgery 14 (14%)
VNS add-on therapy 12 (12%)
a According to ICD-10.Statistics
Baseline group differences were tested by non-para-
metric tests (x2-test, Mann—Whitney U-test). The
hypothesis of this study was tested by univariate
repeated measures ANOVA including bodyweight as
dependent variable, the experimental condition
(extended vs. standard counseling) as a group factor
and time of measurement (baseline, 3- and 6-month
follow-up) as the within-subject factor. Further
tests were applied in an explorative way; non-para-
metric tests were preferred (Friedman test, Spear-
man’s rank correlation and others). The significance
level was defined by a = .05 for all statistical tests.Results
Sixty-one patients (62%) completed the study proto-
col. Four and six patients dropped out for unknown
reasons before the 3- and 6-month follow-up, respec-
tively. In addition, 16 (16%) and 11 patients (11%)
discontinued pregabalin medication before the 3-
and 6-month follow-up, respectively (overall prema-
ture study exit rate: 38%). Four patients decided toTable 2 Bodyweight during pregabalin add-on therapy
Baseline
N 61
Bodyweight (kg) 74.9 (15.1)
Body Mass Index 24.9 (4.0)
Note: Group means and standard deviations (in parentheses) are gwithdraw frompregabalin at the study exit. Themain
reasons for premature study exits were side effects
(18 patients, including weight gain: 2 patients) or
lack of therapeutic effect (5 patients). The follow-up
visits scheduled for 3 and 6 months were actually
doneat 3.4 (0.9;median3.3) and7.5 (1.7;median
7.0) months after baseline.
Medication
The average daily dosage of pregabalin was 296
(S.D.  92; median: 300) mg at the 3-month fol-
low-up and 382 (S.D.  158) (median: 375) mg at the
6-month follow-up in patients who completed the
study. The baseline medication was reduced in 14
and increased in 4 patients during the study but
remained unchanged in the majority of patients
(71%). Medication changes were not different for
both experimental groups and only in one patient
topiramate as a drug known to be associated with
weight changes was reduced.
Bodyweight gain
Mean bodyweight (kg) and body mass indices during
the study are shown in Table 2. To avoid sample
selection effects only patients who completed
the study design were included. The bodyweight
data were missing in one patient for the 6-month
follow-up.
As compared to the baseline, the mean body-
weight increase in individual patients was 2.5 kg
(S.D.  3.7 kg; median: 2.0 kg) and 4.0 kg (S.D. 
4.1 kg; median: 4.0 kg; N = 60) at the 3- and 6-
month follow-up, respectively. The body mass index
increment was 0.9 (S.D.  1.3; median: 0.6) and 1.4
(S.D.  1.4; median: 1.3) for the 3- and 6-month
follow-up, respectively. According to ICD-10 weight
classes (low weight, normal weight, overweight,
obesity grade I; see section Methods), 2 patients
decreased their weight class but 11 and 13 patients
changed to next higher weight class at the 3- and 6-
month follow-up; at the 6-month follow-up 2
patients were even two classes higher as compared
to their baseline category. Furthermore, 17 (28%)
and 25 patients (41%) had a bodyweight gain of
greater than 5 kg at the 3- and 6-month follow-
up, respectively.3 months 6 months
61 60
77.4 (15.1) 78.2 (14.1)
25.8 (4.2) 26.1 (3.8)
iven.
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For patients who completed the study, the rando-
mization procedure yielded 26 patients with
extended counseling and 35 patients with standard
clinical counseling. No significant group differences
regarding the general and clinical variables were
obtained between both groups at the baseline (x2
and Mann—Whitney tests). Baseline medication
was changed in 11 patients from the extended
counseling group and in 7 patients from the standard
counseling group (x2-test, p = .15). A significant
interaction effect of ‘time  experimental condi-
tion’ (F = 5.2, p = .03) on pregabalin dosage (mg)
indicated that the dosage was significantly more
increased from the 3- to 6-month follow-up in the
standard counseling group (291  74 mg vs.
415  164 mg) as compared to the extended coun-
seling group (303  113 mg vs. 338  141 mg) which
confounds the experimental factor ‘counseling’.
The mean bodyweight measures during the study
of both groups are shown in Fig. 1.
A repeated measures ANOVA revealed a signifi-
cant main effect of the factor ‘time’ on bodyweight
(kg) (F = 28.2, p < .001) indicating weight gain inFigure 1 Bodyweight gain during pregabalin add-on
therapy. Means and standard deviations of body weight
gains are shown. (A) Bodyweight gain (in kg) and (B) body
mass index (BMI). Only the factor ‘time’ was significant
(repeated measures ANOVA, F = 28.2, p < .001). EXT:
extended patient counseling; STD: standard counseling.the entire sample during the study. There was no
main effect of the factor ‘group’ (F = 1.35, p = .25)
and no interaction effect ‘time  group’ (F = .16,
p = .85) thus giving no evidence for an effect of the
experimental counseling condition on bodyweight
gain during the study.
Other factors
Pregabalin specific effects on bodyweight gain were
tested but no correlations of weight gain (kg) with
absolute dosage (mg), relative dosage (mg/kg,
dosage divided by baseline bodyweight), or categor-
ized dosage (more or less than 300 mg) of pregabalin
were found at any time point throughout the study.
Furthermore, neither baseline body measures nor
the clinical variables were correlated with weight
gain during the study. However, in an explorative
analysis the number of baseline anticonvulsant med-
ications turned out to be significantly correlated
with weight gain from baseline to the 3-month
follow-up (Spearman’s rank correlation, r = .32,
p < .05) indicating a role of the total drug load
for bodyweight gain under pregabalin therapy
(see Fig. 2).
Controlling the effects of the number of antic-
onvulsant drugs as a covariate in the repeated
measures ANOVA yielded a different pattern of
results. The main effect of ‘time’ was lost
(F = 1.9, p = .16) but the interaction effect ‘time -
 number of anticonvulsant drugs’ was significant
(F = 3.2, p < .05) indicating that weight gain might
not depend on pregabalin per se but on interaction
of pregabalin with a high anticonvulsant drug load.
Again the experimental factor ‘counseling condi-
tion’ revealed no main effect, and did not interact
with bodyweight gain. No specific pharmaceutical
combination could be revealed as a risk factor for
bodyweight gain.Figure 2 Bodyweight gain (3 months) under pregabalin
treatment and number of AED. Spearman’s rank correla-
tion of number of AED and bodyweight gain: r = .32
( p < .05).
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Table 3 Seizure outcome
3 months 6 months
N ATP (N = 61) ITT (N = 98) N ATP (N = 61) ITT (N = 98)
Median % reduction 38% 33%
Responder ratea 28 46% 29% 26 43% 27%
Seizure free rate 4 7% 4% 5 8% 5%
ATP: according-to-protocol sample; ITT: intent-to-treat sample.
a Response is defined as a 50%-reduction of seizure frequency as compared to baseline.Seizure outcome and tolerability
The seizure outcome is given in Table 3.
Responder rates are given related to both the
according-to-protocol (N = 61) and the intent-to-
treat sample (N = 98). The median seizure %-reduc-
tion in study completers was 38% and 33% (N = 61) at
the 3- and 6-month follow-up, respectively, indicat-
ing an early onset of the anticonvulsant effect. None
of the patients who previously underwent epilepsy
surgery (N = 10, 16%) experienced seizure response
at the 6-month follow-up (x2 = 8.9, p < .05). No
other correlations with general or clinical variables
were obtained. In particular, seizure outcome and
bodyweight changes were not correlated.
As mentioned above, side effects were a major
reason for the premature study exit. However, the
Adverse Event Profile scores were unchanged by
pregabalin (mean score of 40 for all time points,
rate of patients with scores greater than 45 at about
30%). Bodyweight gain was neither correlated with
Adverse Event Profile total score nor with item 14
(bodyweight gain).Discussion
This study addressed bodyweight gain as a side
effect of the new anticonvulsant pregabalin. Find-
ings indicate a dosage independent and sustained
effect of this drug on bodyweight during 6 months of
observation with a group median of 4.0 kg. Forty-
one percent of the patients who completed the
study had a bodyweight increase of more than
5 kg. Body weight gain was more expressed during
the first 3 months but continued until the end of the
study. Thus, bodyweight gain was confirmed as a
frequent adverse effect of pregabalin in the treat-
ment of epilepsy. However, further explorative ana-
lyses revealed that the number of anticonvulsant
drugs, representing total antiepileptic drug load, is
an essential mediator of the bodyweight gain effect
of pregabalin. If re-analyses of former data or future
studies confirm this finding, the risk of bodyweight
gain may be more limited to patients receiving
polytherapy. Bodyweight gain was neither reflectedby Adverse Event Profile total scores nor by the
score of the bodyweight gain item of this question-
naire (#14) indicating that subjective evaluations
are rather independent of the objective burden. A
third of the patients (N = 37) prematurely exited the
study due to side effects or the lack of therapeutic
effect but only two of the patients discontinued
pregabalin medication due to bodyweight gain.
The embedded randomized controlled trial
showed that a short patient counseling program
on bodyweight control was without any effect
although a stronger increase of pregabalin dosages
from the 3- to 6-month follow-up in the standard
counseling condition biased the study towards posi-
tive effects of counseling. Thus, within the organi-
zational framework of an outpatient clinic, the risk
of bodyweight gain under pregabalin treatment
could not be controlled efficiently. This does not
preclude that more extensive interventional pro-
grams together with a more efficient control of
patient compliance may be more successful.
The mechanisms underlying bodyweight gain due
to anticonvulsant therapies arenot fully clear yet and
may differ between drugs.1,2 Firstly, increased food
uptake may occur in the consequence of peripheral
mechanisms relying on drug-induced lowering of the
blood glucose level (e.g., due to increased insulin or
decreased carnitine levels) or more directly on cen-
tralmechanisms underlying appetite regulation. Sec-
ondly, drugs may alter energy consumption (e.g.,
sedating effects by alteredGABAergic inhibitory neu-
rotransmission). Thirdly, bodyweight may increase
due to an anti-diuretic effect of the drug and
increased storage of water in the tissue (oedema).9
The design of this present study does not allow a
thorough analysis of the mechanisms underlying
bodyweight gain under pregabalin treatment. For
example, bodyweight measurement did not include
a body fat andwater percentage analysis. Therefore,
it is unclear whether bodyweight gain resulted from
metabolic changes, i.e. increased food uptake or
decreased energy consumption, anti-diuretic effects
or both. Freynhagen et al. reported that pregabalin
as a new treatment for neuropathic pain produced
bodyweight gain but did not affect diabetes control
(blood glucose level).9 Several patients of that study
332 C. Hoppe et al.showed peripheral oedema indicating a possible con-
tribution of an anti-diuretic effect. Of course,
extended counseling aiming at the control of energy
uptakeandconsumptionwouldbe ineffective regard-
ing possible anti-diuretic effects of pregabalin. How-
ever, it appears unlikely that a median bodyweight
gain of 4.0 kg during 6 months could be explained by
an anti-diuretic mechanism only. Furthermore, this
present study shows an important contribution of the
total anticonvulsant drug load indicating cumulative
effects of the entire medication on bodyweight
alteration instead of a specific pregabalin effect.Conclusions
Bodyweight gain may be a risk during pregabalin
treatment in epilepsy particularly in patients with
high anticonvulsant drug load. This risk cannot be
controlled by extended counseling on bodyweight
control under the usual organizational conditions of
an outpatient clinic.Conflicts of interest
The authors have reported no conflicts of interest.Appendix A
Patient handout: Bodyweight Control under Lyr-
icaTM (pregabalin) Treatment
Dear Patient–—studies have confirmed that Lyri-
caTM (pregabalin) is an efficient and well-tolerated
anticonvulsant drug. However, one of the possible
side effects is bodyweight gain. We want to give you
some further information on how you may prevent
this side effect.
Bodyweight gain is only possible if the energy
taken up by eating and drinking (calories) is higher
than the energy actually needed by the body. The
body already consumes a lot of energy just to main-tain the basic functions (e.g., body temperature)
but also for the daily activities. Therefore, we ask
you to observe the following rules:Rule 1: Even if you get a bigger appetite under
LyricaTM (pregabalin) treatment try not to
eat or to drink (except of water or tea)
more than until now!Rule 2: However, if you can not resist eating or
drinking more than compensating this
increased energy uptake by increased bod-
ily activity, walk with a brisk pace for
30 min each day or engage in sports. Find
a physical exercise that gives you pleasure.Rule 3: Check your bodyweight each Monday morn-
ing before eating. Keep the bodyweight
diary attached and bring it with you to each
follow-up at the clinic. (A bodyweight diary
was attached.)References
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